This session covers the importance of representative enrollment in Phase 3 Lupus trials, Biogen’s approach to setting and achieving these goals, and how patient-focused strategies improve clinical trial integrity and outcomes.
Learning Objectives
1. Understand the key challenges in representative enrollment in Phase 3 Lupus clinical trials. 2. Learn how Biogen approached setting enrollment goals that reflect the epidemiology of the disease and specific strategies developed and initiatives executed to achieve these goals. 3. Understand the importance of representative enrollment on trial outcomes and patient care and how this is achievable
Tuesday June 16, 2026 11:40am - 12:10pm EDT Content HubThe Pennsylvania Convention Center 1101 Arch Street Philadelphia, PA 19107 USA
